CAR

Celularity Publishes New Data in Frontiers in Immunology Demonstrating Placental-derived Natural Killer Cells (CYNK) Recognized and Eliminated Influenza A Virus (IAV)-infected Cells In Vitro

Retrieved on: 
Monday, September 26, 2022

Celularitys NK platform propagates placenta-derived hematopoietic stem cells (HSCs) and differentiates them into NK cells.

Key Points: 
  • Celularitys NK platform propagates placenta-derived hematopoietic stem cells (HSCs) and differentiates them into NK cells.
  • The study demonstrated how IAV sensitizes infected cells for targeting by CYNK-001 via multiple stress ligand and NK receptor activating pathways.
  • NK cells, an innate immune component, are important in defense against IAV infection by killing IAV-infected cells and producing cytokines as part of the innate immune response.
  • The CDC estimates influenza costs the United States USD 10.4 billion annually in direct costs for hospitalizations and outpatient visits for adults.

TILT Biotherapeutics Collaborates with MSD on Immunotherapy Clinical Trial in Checkpoint Inhibitor Refractory Non-Small Cell Lung Cancer

Retrieved on: 
Monday, September 26, 2022

This Phase I, open label, dose escalation trial will include 12 to 24 patients with immune checkpoint inhibitor refractory non-small cell lung cancer (NSCLC).

Key Points: 
  • This Phase I, open label, dose escalation trial will include 12 to 24 patients with immune checkpoint inhibitor refractory non-small cell lung cancer (NSCLC).
  • TILT Biotherapeutics CEO, Akseli Hemminki, a cancer clinician who has personally treated hundreds of cancer patients, said, We already have clinical trials running in Europe and the USA in several cancer types, including ovarian cancer, head and neck cancer, and melanoma.
  • We are planning several more, one of which is this new collaboration in NSCLC with our collaborator MSD.
  • TILT-123 has demonstrated a 100% response rate in pre-clinical cancer models in vivo, and it is currently in Phase 1 clinical trials.

Allogene Therapeutics Announces Participation in the Jefferies Cell and Genetic Medicine Summit

Retrieved on: 
Friday, September 23, 2022

The webcast will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section.

Key Points: 
  • The webcast will be posted to the Company's website at www.allogene.com under the Investors tab in the News and Events section.
  • Following a live webcast, a replay will be available on the Company's website for approximately 30 days.
  • Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T) products for cancer.
  • AlloCAR T is a trademark of Allogene Therapeutics, Inc.

Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology & HemeOnc Conference

Retrieved on: 
Friday, September 23, 2022

SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the Cantor Oncology, Hematology & HemeOnc Conference on Wednesday, September 28, 2022 at the NY Palace Hotel in New York City.

Key Points: 
  • SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the Cantor Oncology, Hematology & HemeOnc Conference on Wednesday, September 28, 2022 at the NY Palace Hotel in New York City.
  • Oncternal Therapeuticsis a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need.
  • Oncternal pursues drug development targeting promising, yet untapped biological pathways implicated in cancer generation or progression, focusing on hematological malignancies and prostate cancer.
  • Oncternal is also developing ONCT-808 , an autologous chimeric antigen receptor T (CAR T) cell therapy that targets ROR1.

Malaysian Genomics Grows Presence in Thailand

Retrieved on: 
Friday, September 23, 2022

Acquest is a well-established provider of various cell therapies to hospitals, specialist doctors, and patients in Thailand.

Key Points: 
  • Acquest is a well-established provider of various cell therapies to hospitals, specialist doctors, and patients in Thailand.
  • Chief Executive Officer of Malaysian Genomics, Encik Sasha Nordin, said, "We are looking forward to a fruitful relationship with our Thai partners, Salus and Acquest.
  • We look forward to collaborating with Malaysian Genomics and with Salus Healthcare on research and development involving cell regeneration products."
  • Malaysian Genomics Resource Centre Berhad: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/
    Copyright 2022 ACN Newswire .

NCCN Updates Recommendations for COVID-19 Vaccination with Information on Bivalent Vaccines, Children with Cancer, and Other Developments

Retrieved on: 
Thursday, September 22, 2022

PLYMOUTH MEETING, Pa., Sept. 22, 2022 /PRNewswire/ -- Today, the National Comprehensive Cancer Network® (NCCN®)—an alliance of leading cancer centers—released updated recommendations from the NCCN Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis. This latest evidence-based, expert consensus-formulated summary on cancer and COVID-19 vaccination and prevention is available for free at NCCN.org/covid-19. Significant revisions include new recommendations for the recently-approved bivalent vaccines and advice on protecting children with cancer.

Key Points: 
  • This latest evidence-based, expert consensus-formulated summary on cancer and COVID-19 vaccination and prevention is available for free at NCCN.org/covid-19 .
  • Significant revisions include new recommendations for the recently-approved bivalent vaccines and advice on protecting children with cancer.
  • The NCCN Guidelines for Patients provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation .
  • Visit NCCN.org for more information and follow NCCN on Facebook @NCCNorg , Instagram @NCCNorg , and Twitter @NCCN .

Emercell and Cell-Easy Sign a Strategic Agreement for the Scale-up and Manufacturing of NK-001

Retrieved on: 
Thursday, September 22, 2022

Emercell SAS (Emercell) and Cell-Easy SAS (Cell-Easy) announced today the signing of a strategic agreement for the scale-up and manufacturing of Emercells lead product.

Key Points: 
  • Emercell SAS (Emercell) and Cell-Easy SAS (Cell-Easy) announced today the signing of a strategic agreement for the scale-up and manufacturing of Emercells lead product.
  • Its patented manufacturing process allows a complete industrialization by using the same batch of NK cells for multiple patients.
  • Cell-Easy is an analytics-driven Contract Development and Manufacturing Organization (CDMO) specialized in the production of Gene-modified Cell and Cell Therapy products.
  • Emercell has signed a strategic agreement with Cell-Easy specialized in the development and production of ATMP.

Precision BioSciences to Participate in Upcoming Jefferies Cell & Genetic Medicine Summit

Retrieved on: 
Thursday, September 22, 2022

Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the Jefferies Cell & Genetic Medicine Summit taking place September 29-30, 2022.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the Jefferies Cell & Genetic Medicine Summit taking place September 29-30, 2022.
  • Details for the company presentation are as follows:
    The presentation will be available via a recorded webcast accessible on Precisions website in the Investors section under Events & Presentations: https://investor.precisionbiosciences.com/events-and-presentations .
  • Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS genome editing platform.
  • ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.

GenScript and Gladstone-UCSF Institute of Genomic Immunology Collaborate on Groundbreaking Non-Viral Cell Therapy Study

Retrieved on: 
Thursday, September 22, 2022

PISCATAWAY, N.J., Sept. 22, 2022 /PRNewswire/ -- GenScript USA Inc., the world's leading life-science research tools and services provider, is collaborating with researchers at the Gladstone-UCSF Institute of Genomic Immunology to advance the development of new, non-viral cell therapies that modify genomic sequences in the pursuit of more effective cell therapy products while limiting the cellular toxicity that is typically associated with previously available methods.

Key Points: 
  • A new study, published in Nature Biotechnology , details methods for achieving highly efficient non-viral knock-in using GenScript's GenExactsingle-strand DNA (ssDNA) modified with Cas9-target sequences (CTS).
  • However, difficulties manufacturing large amounts of clinical-grade viral vectors have delayed getting cell therapies to patients.
  • "We are very proud to have collaborated on this groundbreaking scale-up work by the talented team at Gladstone and UCSF.
  • ", said first author Brian Shy, MD, PhD, a former clinical fellow in the lab of Alex Marson, MD, PhD, director of the Gladstone-UCSF Institute of Genomic Immunology.

Labroots Announces Full Three-Day Agenda for its 10th Annual Cancer Research & Immuno-Oncology Week Event, Held on October 4-6, 2022

Retrieved on: 
Wednesday, September 21, 2022

YORBA LINDA, Calif., Sept. 21, 2022 /PRNewswire-PRWeb/ -- Labroots, the leading scientific social networking website offering premier, interactive virtual events and webinars, is hosting its 10th annual Cancer Research and Immuno-Oncology Week conference on October 4-6, 2022. The three-day content-rich agenda continues to be the go-to-meeting sharing cutting-edge discoveries and novel advancements via invited lectures and thought-provoking discussions to improve the outcomes and treatments of patients with cancer.

Key Points: 
  • Cancer Research & Immuno-Oncology Week offers a prestigious forum for some of the brightest minds in the field to collaborate and share knowledge in emerging topics including cancer research, novel targeted therapies in cancer, immuno-oncology, cell therapy, and cancer research networks, epidemiology and patient advocacy.
  • Use the hashtag #LRcancer to follow the conversation and connect with members of the global Cancer & Oncology Research community!
  • Follow @Cancer_LR on Twitter and @CancerResearchandOncology.LR on Facebook to connect with our specialist Cancer & Oncology writers and stay up to date with the latest news in Cancer & Oncology Research.
  • Contributing to the advancement of science through content sharing capabilities, Labroots is a powerful advocate in amplifying global networks and communities.